Exosome Serums Compared: What Actually Differs Between Them?

Professional exosome serums differ on five practical axes: the source of the exosomes (plant, animal-tissue or human-cell-culture derived), the published particle count per vial, what else is in the formula (PDRN, NAD+, peptides, growth factors), the format (liquid vials vs lyophilised powder plus activator), and the production standard behind them. The marketing layer — "billions of exosomes" — hides most of these differences, so this article sorts the landscape by what a clinic can verify in manufacturer-published data, and shows where the ExoPrime range we distribute sits on each axis.

One regulatory sentence first, because it frames everything: in the EU, exosome products for aesthetics are supplied as cosmetics for topical or transdermal professional use — applied with microneedling or mesotherapy technique per each product's IFU — not as injectable medicinal products. Claims and protocols must stay inside that frame.

What is an exosome serum, in plain terms?

Exosomes are nano-scale extracellular vesicles — membrane-wrapped packets of signalling molecules (proteins, lipids, nucleic acids) that cells use to communicate. In a professional serum, they act as a regenerative signal delivered into freshly microneedled or meso-treated skin, supporting repair, collagen synthesis and inflammation control. They are frequently combined with PDRN (polydeoxyribonucleotides — DNA fragments with documented tissue-repair use) and, in newer formulas, NAD+, the coenzyme central to cellular energy metabolism and sirtuin-mediated repair.

How do exosome sources differ?

Source is the biggest single differentiator, because it drives both the regulatory position and the safety conversation:

• Plant-derived exosomes come from plant cell cultures — the ExoPrime range uses papaya- and apple-line exosomes. Plant sourcing avoids the regulatory and ethical questions attached to human- and animal-derived material, which is why it dominates the EU professional-cosmetics channel.
• Animal-tissue-derived material — rose-of-Jericho aside, the prominent examples are salmon-DNA PDRN serums (a separate but overlapping category) and colostrum/milk-derived exosome products described in their manufacturers' materials.
• Human-cell-derived exosomes (for example from stem-cell culture media) appear in some non-EU markets; their use in EU cosmetics raises unresolved regulatory questions, and mainstream EU-distributed professional lines avoid them.
• Plant-stem-cell brands from Asia — for instance ASCE+®, whose manufacturer describes rose-stem-cell-derived exosomes in a lyophilised powder-plus-activator format — established the category globally and remain the most cited reference points.

Do the "billions of exosomes" numbers mean anything?

Published counts are manufacturer declarations of particle quantity per vial or formula, and they vary by orders of magnitude across the market — from single-digit billions to tens of billions in widely marketed lines. Within the ExoPrime range, the published specification for the body-contouring and CaHA formulas is 100 billion plant-derived exosomes per formula, produced by ultracentrifugation in a Class 100 cleanroom (NASA standard) with antibiotic-free culture.

Counts are comparable only alongside two other declarations: the isolation method (ultracentrifugation is the reference standard) and the production environment. A high count with no stated isolation method or cleanroom class is a marketing number, not a specification — ask every supplier for all three, a habit we recommend in our guide to vetting aesthetic suppliers in the EU.

Where does PDRN fit into the exosome landscape?

PDRN serums and exosome serums are cousins, not rivals: PDRN supplies DNA-fragment building blocks and a well-documented repair stimulus, while exosomes supply cell-to-cell signalling. The market increasingly combines them. In the ExoPrime range, Exoglow PDRN NAD+ is exactly that hybrid — PDRN plus papaya- and apple-derived exosomes plus NAD+ — aimed at tired, stressed skin where repair speed is the goal. Markets tell the same story from the demand side: "PDRN" and salmon-DNA phrases carry search volumes as large as the exosome phrases themselves across Germany, Romania and Türkiye.

What does NAD+ add, and why do variants matter?

NAD+ (nicotinamide adenine dinucleotide) is the coenzyme behind cellular energy metabolism and a required substrate for sirtuins — repair-linked proteins like SIRT1. Formulas pairing exosomes with NAD+ (the EXONAD+ technology across the ExoPrime line) target signal and energy: exosomes instruct the repair, NAD+ funds it. The practical consequence for clinics is variant specialisation within one technology platform:

• Exoglow Face NAD+ — facial skin-quality and anti-ageing series;
• Exoglow PDRN NAD+ — repair-focused hybrid for stressed skin;
• Exoglow Hair NAD+ — follicle-focused scalp protocols with biomimetic peptides, serving the trichology demand that is now the strongest vertical in several of our markets;
• Exopeel NAD+ — two-phase peel with the regeneration step built in;
• Exolime NAD+ and ExoCaha NAD+ — body-contouring and CaHA-firming applications at the published 100-billion count.

One platform with dedicated variants keeps training, consent language and supplier count low — compare that against assembling equivalent coverage from three unrelated brands. The full range sits in our mesotherapy category; serum selection logic by indication is covered in the mesotherapy cocktail guide.

How should a clinic compare exosome serums before buying?

Run every candidate through the same five questions: What is the declared source and isolation method? What count per vial, in what cleanroom class? What carriers and co-actives (PDRN, NAD+, peptides) — and does the variant map fit your menu? What format and in-session workflow (ready liquid vs powder-plus-activator)? And what documentation ships with it — IFU, safety data, batch traceability? Price per session only becomes meaningful after those five are on the table. As official MedRoyal distributor we answer all five in writing with every quotation — request one from any product page, or see wholesale terms for clinic groups, pharmacies and resellers.

FAQ

Are exosome serums injectable?

In the EU they are professional cosmetics for topical and transdermal use — delivered with microneedling or mesotherapy technique per the product IFU, not marketed as injectables. That regulatory position is also what makes them accessible to a wider professional audience than injectable-only categories.

Are plant-derived exosomes weaker than human- or animal-derived ones?

Published head-to-head clinical comparisons across sources are scarce; what differs demonstrably today is the regulatory and safety position, where plant derivation avoids the open questions attached to human- and animal-derived material in EU cosmetics. Evaluate each product on its published data rather than assuming a source hierarchy.

How many sessions does an exosome protocol take?

Published protocols across the category typically run as a series of 3–5 sessions at 2–4-week intervals, with maintenance per response — the ExoPrime materials follow the same shape. Exact counts and intervals are IFU-level parameters per product and indication.

Can exosome serums be combined with other treatments?

Yes — pairing with microneedling is the default delivery route, and combinations with peels (Exopeel integrates the two), skin boosters or biostimulator plans are common in practice. Sequence per the IFUs involved and standard post-treatment care rules.

Third-party product information above is based on manufacturer-published data at the time of writing; trademarks remain their owners' property, used nominatively with no affiliation or endorsement implied. Last updated: 2026-08-12.